342 related articles for article (PubMed ID: 18213631)
41. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
42. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
[TBL] [Abstract][Full Text] [Related]
43. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
45. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
Galkin AV; Mullen L; Fox WD; Brown J; Duncan D; Moreno O; Madison EL; Agus DB
Prostate; 2004 Nov; 61(3):228-35. PubMed ID: 15368474
[TBL] [Abstract][Full Text] [Related]
46. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
Furukawa J; Wraight CJ; Freier SM; Peralta E; Atley LM; Monia BP; Gleave ME; Cox ME
Prostate; 2010 Feb; 70(2):206-18. PubMed ID: 19790231
[TBL] [Abstract][Full Text] [Related]
47. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
48. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
[TBL] [Abstract][Full Text] [Related]
49. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
Kochuparambil ST; Al-Husein B; Goc A; Soliman S; Somanath PR
J Pharmacol Exp Ther; 2011 Feb; 336(2):496-505. PubMed ID: 21059805
[TBL] [Abstract][Full Text] [Related]
50. Effects of a human compact anti-ErbB2 antibody on prostate cancer.
Malara AE; Fedele C; Aloj L; Arra C; Laccetti P; D'Alessio G; De Lorenzo C
Oncol Rep; 2012 Jul; 28(1):297-302. PubMed ID: 22505344
[TBL] [Abstract][Full Text] [Related]
51. Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer.
Kampa M; Theodoropoulou K; Mavromati F; Pelekanou V; Notas G; Lagoudaki ED; Nifli AP; Morel-Salmi C; Stathopoulos EN; Vercauteren J; Castanas E
J Pharmacol Exp Ther; 2011 Apr; 337(1):24-32. PubMed ID: 21205921
[TBL] [Abstract][Full Text] [Related]
52. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
Zhong Z; Carroll KD; Policarpio D; Osborn C; Gregory M; Bassi R; Jimenez X; Prewett M; Liebisch G; Persaud K; Burtrum D; Wang S; Surguladze D; Ng S; Griffith H; Balderes P; Doody J; Schwartz JD; Youssoufian H; Rowinsky EK; Ludwig DL; Witte L; Zhu Z; Wu Y
Clin Cancer Res; 2010 Feb; 16(4):1191-205. PubMed ID: 20145179
[TBL] [Abstract][Full Text] [Related]
53. Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo.
Ishii K; Imamura T; Iguchi K; Arase S; Yoshio Y; Arima K; Hirano K; Sugimura Y
Endocr Relat Cancer; 2009 Jun; 16(2):415-28. PubMed ID: 19293288
[TBL] [Abstract][Full Text] [Related]
54. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
[TBL] [Abstract][Full Text] [Related]
55. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer.
Carstens RP; Eaton JV; Krigman HR; Walther PJ; Garcia-Blanco MA
Oncogene; 1997 Dec; 15(25):3059-65. PubMed ID: 9444954
[TBL] [Abstract][Full Text] [Related]
56. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
[TBL] [Abstract][Full Text] [Related]
57. Sodium selenite radiosensitizes hormone-refractory prostate cancer xenograft tumors but not intestinal crypt cells in vivo.
Tian J; Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):230-6. PubMed ID: 20615620
[TBL] [Abstract][Full Text] [Related]
58. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
[TBL] [Abstract][Full Text] [Related]
59. Synergistic tumor growth-inhibitory effect of the prostate-specific antigen-activated fusion peptide BSD352 for prostate cancer therapy.
Li B; Zhang LJ; Zhang ZL; Long M; Ren JH; Lin F; Wang X; Wei JX; Dong K; Zhang HZ
Anticancer Drugs; 2011 Mar; 22(3):213-22. PubMed ID: 21150773
[TBL] [Abstract][Full Text] [Related]
60. Preclinical evaluation of the novel multi-targeted agent R1530.
Kolinsky K; Tovar C; Zhang YE; Railkar A; Yang H; Carvajal D; Nevins T; Geng W; Linn M; Packman K; Liu JJ; Zhang Z; Wovkulich P; Ju G; Higgins B
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1585-94. PubMed ID: 21553286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
